3401 Technology Dr.
79 articles with Astellas Pharma
Inscopix and Astellas Initiate Collaboration to Study Neural Activity Patterns in Preclinical Models of Psychiatric Disorders
Inscopix has entered into a research collaboration with Astellas Research Institute of America LLC, a subsidiary of Astellas Pharma Inc., to develop novel preclinical drug screening assays for psychiatric disorders.
Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy
Financial Support for LabCentral Incubators Builds on Astellas' $1 Billion+ Investment in Boston's Life Science Community
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response
Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A Schoeneck., "FibroGen") today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Evrenzo® (generic name: roxadustat) for the treatment of anemia associated with chronic kidney disease (CKD) in dialysis patients.
Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms
Astellas Pharma Inc. announced dosing of the first patient in the SKYLIGHT 1™ Phase 3 pivotal trial for fezolinetant, an investigational oral, non-hormonal compound being studied for the treatment of moderate-to-severe vasomotor symptoms – i.e., hot flashes and night sweats associated with menopause.
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology-
Otsuka Chemical Co., Ltd. announces that it has succeeded part of the Cefixime business from Astellas Pharma, Inc..
Vect-Horus will use its proprietary technology VECTrans® to transport Astellas’ antibody to the brain for the treatment of CNS diseases.
LPIXEL Inc., a leader in image analysis and processing technology in life science and medical research, is pleased to announce the initiation of the artificial intelligence (AI) system development for cell evaluation with Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”).
Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
Seattle Genetics, Inc. and Astellas Pharma Inc. announced that data from the first cohort of a pivotal phase 2 clinical trial known as EV-201 demonstrated that the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44 percent.
Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
Astellas Pharma Inc. and Seattle Genetics, Inc. announced that data from the first cohort of a pivotal phase 2 clinical trial known as EV-201 demonstrated that the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44 percent
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)
Astellas Pharma Inc. announced that the U.S. Food and Drug Administration approved a supplemental New Drug Application to update the U.S. product labeling for XOSPATA® to include final analysis data from the ADMIRAL trial.
Under the terms of the agreement, Modulus plans to design, evaluate and optimize lead compounds for this target to rapidly identify a novel clinical candidate through leveraging its cutting-edge computational drug discovery platform.
New Data Show Mirabegron Reduced OAB Symptoms in Men with Benign Prostatic Hyperplasia Currently Treated with Tamsulosin
Data Presented at the American Urological Association 2019 Annual Meeting
Astellas ranked 22nd on the Best Workplaces™ in Canada list, in addition to recognition on the 2019 lists of Best Workplaces™ in Canada for Giving Back, Inclusion and Women
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a research and license agreement in which Astellas Pharma Inc. will access Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology
Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D. "Astellas") today announced results from the Phase 3 ADMIRAL clinical trial comparing XOSPATA® (gilteritinib) to salvage chemotherapy in adult patients with relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer - March 28, 2019
Seattle Genetics, Inc. and Astellas Pharma Inc. announced positive topline results from the first cohort of patients in a pivotal phase 2 single-arm clinical trial known as EV-201.
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Companies Plan to Submit Biologics License Application Later This Year
Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society's Annual Meeting (ENDO)
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced results from a Phase 2b dose-finding study of fezolinetant, presented in an oral session (Abstract OR33-6) at ENDO 2019, the Endocrine Society's annual meeting in New Orleans.